About The Study: Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but their uptake remained limited, with only 3% of eligible patients having ever received a prescription during that period. Furthermore, there were disparities in prescribing of varying magnitude based on race and ethnicity, social vulnerability, and urbanicity, although the absolute differences were small compared with the overall underutilization.